Search

Your search keyword '"Puja Sapra"' showing total 145 results

Search Constraints

Start Over You searched for: Author "Puja Sapra" Remove constraint Author: "Puja Sapra"
145 results on '"Puja Sapra"'

Search Results

51. Abstract 2283: A novel GUCY2C - CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors

52. Abstract 4557: BCMA-CD3 bispecific antibody PF-06863135: Preclinical rationale for therapeutic combinations

53. Abstract A16: A GUCY2c-CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors

54. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions

55. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions

56. The Next Generation of Antibody Drug Conjugates

57. Antibody-drug conjugates: an emerging modality for the treatment of cancer

58. A general approach to site-specific antibody drug conjugates

59. Correction to: Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer

60. Monoclonal antibody-based therapies in cancer: Advances and challenges

61. Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia

62. Lysosomes and Antibody-Drug Conjugates

63. Calicheamicin Antibody‐Drug Conjugates and Beyond

64. Investigational antibody drug conjugates for solid tumors

65. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects

66. Abstract 935: Generation and preclinical characterization of CD123-CPI antibody-drug conjugate (ADC)

67. Abstract 818: NG-HER2 ADC (PF-06804103) is superior to trastuzumab emtansine in a mouse 'avatar' head-to-head clinical trial

68. Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma

69. A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth

70. Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers

71. Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography

72. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?

73. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice

74. Selecting an Optimal Antibody for Antibody- Drug Conjugate Therapy

75. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin

76. Ligand-Targeted Liposomes for Cancer Treatment

77. Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal VincristineversusLiposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab′ Fragments

78. ADVENTURES IN TARGETING

79. Abstract 3095: The development of CPI as a novel, next-generation DNA-targeting payload for ADCs

80. Phenotype of TPBG Gene Replacement in the Mouse and Impact on the Pharmacokinetics of an Antibody-Drug Conjugate

81. Antibody-drug conjugates: an emerging modality for the treatment of cancer

82. Evolving Strategies for Target Selection for Antibody-Drug Conjugates

83. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies

84. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates

85. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

86. Novel DNA-Damaging Linker Payloads Are Active in Models of Acquired Resistance to Calicheamicin and Standard of Care

87. Abstract 1220: A novel PTK7-targeted antibody-drug conjugate eliminates tumor-initiating cells and induces sustained tumor regressions

88. Abstract 1206: Preclinical evaluation of targeting Notch-3 in breast cancer

89. Abstract 868: Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors

90. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells

91. Advances in bispecific biotherapeutics for the treatment of cancer

92. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer

93. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor

95. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide

96. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model

97. Abstract 644: Impact of conjugation site on pharmacokinetics and off-target toxicity of site-specific antibody drug conjugates

98. Abstract 1469: Patient derived xenograft (PDX) models: improving predictability of experimental cancer therapies

99. Abstract 565: Circulating tumor cell (CTC) detection and 5T4 characterization in breast, ovarian, and lung cancer patients on active therapy

100. Abstract 1697: Therapeutic targeting the NOTCH3 receptor with antibody drug conjugates

Catalog

Books, media, physical & digital resources